These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 22052466)
1. Plasma levels of complement 4a protein are increased in Alzheimer's disease. Bennett S; Grant M; Creese AJ; Mangialasche F; Cecchetti R; Cooper HJ; Mecocci P; Aldred S Alzheimer Dis Assoc Disord; 2012; 26(4):329-34. PubMed ID: 22052466 [TBL] [Abstract][Full Text] [Related]
2. Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease. Güntert A; Campbell J; Saleem M; O'Brien DP; Thompson AJ; Byers HL; Ward MA; Lovestone S J Alzheimers Dis; 2010; 21(2):585-96. PubMed ID: 20571216 [TBL] [Abstract][Full Text] [Related]
3. Plasma biomarkers for mild cognitive impairment and Alzheimer's disease. Song F; Poljak A; Smythe GA; Sachdev P Brain Res Rev; 2009 Oct; 61(2):69-80. PubMed ID: 19464319 [TBL] [Abstract][Full Text] [Related]
4. Quantitative proteomic analysis of serum proteins in patients with Parkinson's disease using an isobaric tag for relative and absolute quantification labeling, two-dimensional liquid chromatography, and tandem mass spectrometry. Zhang X; Yin X; Yu H; Liu X; Yang F; Yao J; Jin H; Yang P Analyst; 2012 Jan; 137(2):490-5. PubMed ID: 22108571 [TBL] [Abstract][Full Text] [Related]
5. Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation. Maher SG; McDowell DT; Collins BC; Muldoon C; Gallagher WM; Reynolds JV Ann Surg; 2011 Nov; 254(5):809-16; discussion 816-7. PubMed ID: 22005152 [TBL] [Abstract][Full Text] [Related]
6. Blood and plasma-based proteomic biomarker research in Alzheimer's disease. Lista S; Faltraco F; Prvulovic D; Hampel H Prog Neurobiol; 2013; 101-102():1-17. PubMed ID: 22743552 [TBL] [Abstract][Full Text] [Related]
7. Plasma metabolic profiling of Alzheimer's disease by liquid chromatography/mass spectrometry. Li NJ; Liu WT; Li W; Li SQ; Chen XH; Bi KS; He P Clin Biochem; 2010 Aug; 43(12):992-7. PubMed ID: 20457143 [TBL] [Abstract][Full Text] [Related]
8. Proteomic identification of lower apolipoprotein A-I in Alzheimer's disease. Liu HC; Hu CJ; Chang JG; Sung SM; Lee LS; Yuan RY; Leu SJ Dement Geriatr Cogn Disord; 2006; 21(3):155-61. PubMed ID: 16391478 [TBL] [Abstract][Full Text] [Related]
9. A proof-of-principle gel-free proteomics strategy for the identification of predictive biomarkers for the onset of pre-eclampsia. Blankley RT; Gaskell SJ; Whetton AD; Dive C; Baker PN; Myers JE BJOG; 2009 Oct; 116(11):1473-80. PubMed ID: 19663911 [TBL] [Abstract][Full Text] [Related]
10. Complement component C4A and apolipoprotein A-I in plasmas as biomarkers of the severe, early-onset preeclampsia. Zhang H; Zhang Y; Yang F; Li L; Liu S; Xu Z; Wang J; Sun S Mol Biosyst; 2011 Aug; 7(8):2470-9. PubMed ID: 21677994 [TBL] [Abstract][Full Text] [Related]
11. The role of proteomics in dementia and Alzheimer's disease. Zellner M; Veitinger M; Umlauf E Acta Neuropathol; 2009 Jul; 118(1):181-95. PubMed ID: 19259691 [TBL] [Abstract][Full Text] [Related]
12. Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Sultana R; Boyd-Kimball D; Poon HF; Cai J; Pierce WM; Klein JB; Merchant M; Markesbery WR; Butterfield DA Neurobiol Aging; 2006 Nov; 27(11):1564-76. PubMed ID: 16271804 [TBL] [Abstract][Full Text] [Related]
13. Decreased expression and increased oxidation of plasma haptoglobin in Alzheimer disease: Insights from redox proteomics. Cocciolo A; Di Domenico F; Coccia R; Fiorini A; Cai J; Pierce WM; Mecocci P; Butterfield DA; Perluigi M Free Radic Biol Med; 2012 Nov; 53(10):1868-76. PubMed ID: 23000119 [TBL] [Abstract][Full Text] [Related]
15. Combination of p53(ser15) and p21/p21(thr145) in peripheral blood lymphocytes as potential Alzheimer's disease biomarkers. Tan M; Wang S; Song J; Jia J Neurosci Lett; 2012 May; 516(2):226-31. PubMed ID: 22503900 [TBL] [Abstract][Full Text] [Related]
16. Redox proteomics identification of oxidatively modified proteins in Alzheimer's disease brain and in vivo and in vitro models of AD centered around Abeta(1-42). Sultana R; Perluigi M; Butterfield DA J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Mar; 833(1):3-11. PubMed ID: 16236561 [TBL] [Abstract][Full Text] [Related]
18. Finding a pathological diagnosis for Alzheimer's disease: are inflammatory molecules the answer? Bhamra MS; Ashton NJ Electrophoresis; 2012 Dec; 33(24):3598-607. PubMed ID: 23161254 [TBL] [Abstract][Full Text] [Related]
19. Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease. Jung SM; Lee K; Lee JW; Namkoong H; Kim HK; Kim S; Na HR; Ha SA; Kim JR; Ko J; Kim JW Neurosci Lett; 2008 May; 436(2):153-7. PubMed ID: 18378077 [TBL] [Abstract][Full Text] [Related]
20. Increased plasma levels of soluble CD40, together with the decrease of TGF beta 1, as possible differential markers of Alzheimer disease. Mocali A; Cedrola S; Della Malva N; Bontempelli M; Mitidieri VA; Bavazzano A; Comolli R; Paoletti F; La Porta CA Exp Gerontol; 2004 Oct; 39(10):1555-61. PubMed ID: 15501026 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]